A fast and thorough method for genetic testing in lung cancer.
A Rapid and Comprehensive Approach for Clinical Genomic Profiling in Lung Cancer
This study is working on a fast and easy way to test for important genetic changes in all types of cancer, especially lung cancer, to help doctors find the best treatments for patients, using a new method that can give results in just three days.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-11115625 on NIH RePORTER |
What this research studies
This research aims to improve precision medicine by creating a quick and comprehensive method for molecular diagnostic testing applicable to all cancer subtypes, particularly lung cancer. The approach focuses on identifying specific genomic changes that are crucial for determining the best treatment options. By utilizing a novel technique called ChromoSeq, the researchers can analyze a wide range of mutations from minimal DNA samples, significantly reducing the failure rate of current testing methods. This innovative method promises to deliver complete genomic profiles in as little as three days, enhancing the diagnostic process for cancer patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with lung cancer or other solid tumors who require genomic profiling for treatment decisions.
Not a fit: Patients with cancer types that are not included in the genomic profiling or those who do not require genomic testing may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and timely diagnoses for lung cancer patients, ultimately improving treatment outcomes.
How similar studies have performed: Previous research has demonstrated success with similar genomic profiling approaches, indicating a promising avenue for advancing cancer diagnostics.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Duncavage, Eric J — Washington University
- Study coordinator: Duncavage, Eric J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.